COVID-19 in diabetic patients: Related risks and specifics of management.
Acidosis, Lactic
/ chemically induced
Betacoronavirus
/ physiology
COVID-19
Comorbidity
Coronavirus Infections
/ complications
Critical Illness
/ epidemiology
Diabetes Mellitus, Type 2
/ complications
Diabetic Ketoacidosis
/ chemically induced
Humans
Mass Screening
/ methods
Metformin
/ therapeutic use
Obesity
/ complications
Pandemics
Pneumonia, Viral
/ complications
Prediabetic State
/ complications
Renin-Angiotensin System
/ physiology
Risk Factors
Risk Management
SARS-CoV-2
Severity of Illness Index
Sodium-Glucose Transporter 2 Inhibitors
/ therapeutic use
Withholding Treatment
COVID-19
Comorbidities
Comorbidités
Diabetes
Diabète
Obesity
Obésité
Pneumonia
Pneumonie
SARS-CoV-2
Journal
Annales d'endocrinologie
ISSN: 2213-3941
Titre abrégé: Ann Endocrinol (Paris)
Pays: France
ID NLM: 0116744
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
received:
04
05
2020
revised:
10
05
2020
accepted:
10
05
2020
pubmed:
16
5
2020
medline:
11
6
2020
entrez:
16
5
2020
Statut:
ppublish
Résumé
Diabetes is among the most frequently reported comorbidities in patients infected with COVID-19. According to current data, diabetic patients do not appear to be at increased risk of contracting SARS-CoV-2 compared to the general population. On the other hand, diabetes is a risk factor for developing severe and critical forms of COVID-19, the latter requiring admission to an intensive care unit and/or use of invasive mechanical ventilation, with high mortality rates. The characteristics of diabetic patients at risk for developing severe and critical forms of COVID-19, as well as the prognostic impact of diabetes on the course of COVID-19, are under current investigation. Obesity, the main risk factor for incident type 2 diabetes, is more common in patients with critical forms of COVID-19 requiring invasive mechanical ventilation. On the other hand, COVID-19 is usually associated with poor glycemic control and a higher risk of ketoacidosis in diabetic patients. There are currently no recommendations in favour of discontinuing antihypertensive medications that interact with the renin-angiotensin-aldosterone system. Metformin and SGLT2 inhibitors should be discontinued in patients with severe forms of COVID-19 owing to the risks of lactic acidosis and ketoacidosis. Finally, we advise for systematic screening for (pre)diabetes in patients with proven COVID-19 infection.
Identifiants
pubmed: 32413342
pii: S0003-4266(20)30068-8
doi: 10.1016/j.ando.2020.05.001
pmc: PMC7217100
pii:
doi:
Substances chimiques
Sodium-Glucose Transporter 2 Inhibitors
0
Metformin
9100L32L2N
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
101-109Informations de copyright
Copyright © 2020. Published by Elsevier Masson SAS.
Références
N Engl J Med. 2020 May 1;:
pubmed: 32356627
Obesity (Silver Spring). 2020 Apr 30;:
pubmed: 32352637
Am J Physiol Endocrinol Metab. 2015 Oct 1;309(7):E621-31
pubmed: 26389599
Diabetes Metab Syndr. 2020 Apr 9;14(4):303-310
pubmed: 32298981
Zhonghua Xin Xue Guan Bing Za Zhi. 2020 Mar 02;48(0):E004
pubmed: 32120458
Diabetes Obes Metab. 2020 Apr 20;:
pubmed: 32314455
Ann Endocrinol (Paris). 2020 Jun;81(2-3):63-67
pubmed: 32370986
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632
N Engl J Med. 2020 Apr 23;382(17):1653-1659
pubmed: 32227760
AACN Clin Issues. 2004 Jan-Mar;15(1):45-62
pubmed: 14767364
Am J Respir Crit Care Med. 2017 Nov 1;196(9):1113-1121
pubmed: 28481621
Acta Diabetol. 2010 Sep;47(3):193-9
pubmed: 19333547
Int J Mol Sci. 2017 Mar 05;18(3):
pubmed: 28273875
Obesity (Silver Spring). 2020 Apr 9;:
pubmed: 32271993
Clin Microbiol Infect. 2020 Apr 3;:
pubmed: 32251842
Int J Infect Dis. 2020 Mar;92:208-213
pubmed: 31978583
JAMA. 2020 Mar 23;:
pubmed: 32203977
N Engl J Med. 2020 Apr 17;:
pubmed: 32302078
J Endocrinol Invest. 2020 Jun;43(6):867-869
pubmed: 32222956
Lancet Diabetes Endocrinol. 2020 Jun;8(6):546-550
pubmed: 32334646
Clin Infect Dis. 2020 Apr 09;:
pubmed: 32271368
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Cell Metab. 2020 Jun 2;31(6):1068-1077.e3
pubmed: 32369736
Diabetes Metab Res Rev. 2020 Mar 31;:e3319
pubmed: 32233013
Allergy. 2020 Feb 19;:
pubmed: 32077115
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Diabetes Care. 2011 Mar;34(3):771-8
pubmed: 21357364
JAMA. 2020 Apr 6;:
pubmed: 32250385
Diabetes Care. 2020 May 14;:
pubmed: 32409502
N Engl J Med. 2001 Nov 8;345(19):1359-67
pubmed: 11794168
Cell. 2020 May 28;181(5):1016-1035.e19
pubmed: 32413319
N Engl J Med. 2020 May 1;:
pubmed: 32356628
JAMA Intern Med. 2020 Mar 13;:
pubmed: 32167524
Obesity (Silver Spring). 2020 May 4;:
pubmed: 32365275
N Engl J Med. 2006 Feb 2;354(5):449-61
pubmed: 16452557
Diabetes Res Clin Pract. 2020 Apr;162:108142
pubmed: 32278764
MMWR Morb Mortal Wkly Rep. 2020 Apr 03;69(13):382-386
pubmed: 32240123
Obesity (Silver Spring). 2020 Apr 27;:
pubmed: 32339391
BMJ. 2020 Mar 26;368:m1091
pubmed: 32217556
Diabetes Metab Syndr. 2020 Apr 17;14(4):395-403
pubmed: 32334395
JCI Insight. 2019 Oct 17;4(20):
pubmed: 31550243
Diabetes Metab Syndr. 2020 May - Jun;14(3):241-246
pubmed: 32247211
JAMA. 2020 Feb 7;:
pubmed: 32031570
N Engl J Med. 2009 Mar 26;360(13):1283-97
pubmed: 19318384
Zhonghua Liu Xing Bing Xue Za Zhi. 2020 Feb 10;41(2):145-151
pubmed: 32064853
J Infect. 2020 Jun;80(6):607-613
pubmed: 32283152
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Viruses. 2019 Jan 14;11(1):
pubmed: 30646565
Obesity (Silver Spring). 2020 Jun;28(6):1005
pubmed: 32237206
Diabetes Res Clin Pract. 2020 May;163:108146
pubmed: 32283128
Eur Respir J. 2020 May 14;55(5):
pubmed: 32217650
Endocr Rev. 2020 Jun 1;41(3):
pubmed: 32294179
Metabolism. 2020 Mar 24;107:154216
pubmed: 32220612
Diabet Med. 2017 Apr;34(4):551-557
pubmed: 27548909
N Engl J Med. 2020 May 21;382(21):2012-2022
pubmed: 32227758
Circ Res. 2020 Jun 5;126(12):1671-1681
pubmed: 32302265
Obesity (Silver Spring). 2020 Apr 21;:
pubmed: 32314861